Related Experiment Video

Updated: Mar 4, 2026

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

14.3K

The world of targeted therapies in kidney cancers: pitfalls, tips and tricks

Alexis Vallard1, Jane-Chloé Trone1, Julien Langrand-Escure1

  • 1Department of Radiation Oncology, Lucien Neuwirth Cancer Institute, Saint-Priest en Jarez, France.

Oncotargets and Therapy
|April 21, 2017
PubMed

Insights

Molecular targeted therapies (TTs) have improved metastatic renal cell carcinoma treatment but can cause rare side effects. Careful management and reporting of these toxicities are crucial for understanding their therapeutic index.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Molecular targeted therapies (TTs) have enhanced prognosis for metastatic renal cell carcinoma (mRCC).
  • Treatment tolerance and adherence are significant concerns in mRCC management due to efficacy/toxicity balance.
  • Oral TTs require optimal patient adherence, making side effect management critical.

Purpose of the Study:

  • To report uncommon and novel side effects associated with sunitinib and sorafenib in mRCC patients.
  • To highlight the importance of multidisciplinary management for unexpected toxicities and efficacies of TTs.
  • To emphasize the need for systematic reporting to understand the real therapeutic index of TTs.

Main Methods:

  • Case series detailing four distinct clinical observations.
  • Inclusion of side effects such as severe vomiting, gout attacks, and scalp dysesthesia.
  • Presentation of a case with significant efficacy using metronomic bevacizumab monotherapy.

Main Results:

  • Sunitinib was associated with grade 3 vomiting during hemodialysis and iterative gout attacks.
  • Sorafenib was linked to grade 3 scalp dysesthesia.
  • Metronomic bevacizumab demonstrated notable efficacy as monotherapy in one case.

Conclusions:

  • TTs for mRCC, while revolutionary, present unique and sometimes un-described side effects.
  • Management of these off-target effects requires careful consideration of comedications and a multidisciplinary approach.
  • Systematic reporting of toxicities and efficacies is essential for a comprehensive understanding of TTs' therapeutic index, especially given unclear physiopathology.
Keywords:
bevacizumabefficacyrenal cell carcinomasorafenibsunitinibtoxicity

More Related Videos

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers12:22

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

34.2K
Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy

Published on: April 29, 2014

17.3K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
554
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
410